Ulrich BEUERS   SITE

  • Liver Int. 2020;40:3042-3050. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. de Vries E, Mazzetti M, Takkenberg B, Mostafavi N, Bikker H, Marzioni M, de Veer R, van A, der Meer, Doukas M, Verheij J, Beuers U. PubMed
  • J Hepatol. 2019;71:153-162. Liver-directed gene therapy results in long term correction of progressive familial intrahepatic cholestasis type 3 in mice. Aronson SJ, Bakker RS, Shi X, Duijst S, Ten Bloemendaal L, de Waart DR, Verheij J, Elferink RPO, Beuers U, Paulusma CC, Bosma PJ. PubMed
  • Nucl Med Commun. 2019;40:388-392. Stress test of liver function using technetium-99m-mebrofenin hepatobiliary scintigraphy. Rassam F, Cieslak KP, Beuers UHW, van Gulik TM, Bennink RJ. PubMed
  • HPB (Oxford). 2018;In press. Scintigraphic liver function and transient elastography in the assessment of patients with resectable hepatocellular carcinoma. Rassam F, Olthof PB, Takkenberg BR, Beuers U, Klümpen HJ, Bennink RJ, van Lienden KP, Besselink MG, Busch OR, Verheij J, van Gulik TM. PubMed
  • Hepatology. 2018;68;1057-1069. Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice.Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, Oude Elferink RPJ, van de Graaf SFJ. PubMed
  • Lancet. 2018;391:2547-2559. Primary sclerosing cholangitis. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. PubMed
  • Sci Rep. 2017;7:15307. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Donkers JM, Zehnder B, van Westen GJP, Kwakkenbos MJ, IJzerman AP, Oude Elferink RPJ, Beuers U, Urban S, van de Graaf SFJ. PubMed
  • Hepatology. 2017;66:1631-1643. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S, de Waart DR, Tolenaars D, van der Meer JHM, Wildenberg M, Beuers U, Oude Elferink RPJ, Schinkel AH, van de Graaf SFJ. PubMed
  • J Hepatol. 2017;67:145-172. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. European Association for the Study of the Liver.  PubMed
  • Gastroenterology. 2017;152:1975-1984. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chaouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. PubMed
  • Liver Int. 2017;37:1554-1561. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-center study. de Vries EM, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. PubMed
  • Dig Dis. 2017;35:217-223. The emerging role of soluble adenylyl cyclase in primary biliary cholangitis. Chang JC, Beuers U, Oude Elferink RP. PubMed
  • Lancet. 2017:389:1114-1123. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE. PubMed
  • Lancet. 2017;389:709-717. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. PubMed
  • Hepatology. 2017; in press. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice. Maroni L, Hohenester SD, van de Graaf SF, Tolenaars D, van Lienden K, Verheij J, Marzioni M, Karlsen TH, Oude Elferink RP, Beuers U. PubMed
  • Liver Int. 2017;37:S123-S129. Management of cholestatic disease in 2017. de Vries E, Beuers U. PubMed
  • J Hepatol. 2015;62:S25-37. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. Beuers U, Trauner M, Jansen P, Poupon R. PubMed
  • Hepatology. 2015;62:207-19. Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice. Slijepcevic D, Kaufman C, Wichers CG, Gilglioni EH, Lempp FA, Duijst S, de Waart DR, Elferink RP, Mier W, Stieger B Beuers U, Urban S, van de Graaf SF. PubMed
  • Clin Rev Allergy Immunol. 2015;48:243-53. Gene replacement therapy for genetic hepatocellular jaundice. van Dijk R, Beuers U, Bosma PJ. PubMed
  • Liver Int. 2015;35:1478-88. Characterization and treatment of persistent hepatocellular secretory failure. van Dijk R, Kremer AE, Smit W, van den Elzen B, van Gulik T, Gouma D, Lameris JS, Bikker H, Enemuo V, Stokkers PC, Feist M, Bosma P, Jansen PL, Beuers U. PubMed
  • Curr Opin Gastroenterol. 2012;28:253-7. The biliary HCO(3)(-) umbrella: experimental evidence revisited. Beuers U, Maroni L, Elferink RO. PubMed
  • Hepatology. 2012;55:173-83. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. PubMed
  • Expert Opin Ther Targets. 2011;15:1173-82.Targeting the ABCB4 gene to control cholesterol homeostasis. Oude Elferink RP, Beuers U. PubMed
  • Dig Dis. 2011;29:62-5. Biliary bicarbonate secretion constitutes a protective mechanism against bile acid-induced injury in man.Hohenester S, Maillette de Buy Wenniger L, Jefferson DM, Oude Elferink RP, Beuers U. PubMed
  • Curr Drug Targets. 2011;12:661-70.The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. Stieger B, Beuers U. PubMed
  • Hepatology. 2010;52:1489-96. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. PubMed
  • J Hepatol. 2008;49:881-3. New light on anion exchangers in primary biliary cirrhosis. Beuers U, Oude-Elferink RP. PubMed
  • Pharmacogenet Genomics. 2007;17:47-60. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. PubMed
  • Nat Clin Pract Gastroenterol Hepatol. 2006;3:318-28.Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Beuers U. PubMed

PubMed

Amsterdam, The Netherlands

Ulrich_Beuers.jpg

Last update: October 2021